Aktis Oncology (AKTS) CMO Akos Czibere Exercises Options, Sells Shares

What Happened

• Akos Czibere, Chief Medical Officer of Aktis Oncology (AKTS), reported option exercise and open-market sales on Sept 23, 2026. He exercised 12,500 options at $4.95 per share (cash paid $61,875) and sold a total of 12,500 common shares in two blocks for combined proceeds of $258,621 (reported as $102,973 and $155,648). The filing also shows a separate derivative entry for 12,500 shares shown as disposed at $0 (derivative transaction).

Key Details

• Transaction date: September 23, 2026; Form 4 filed September 24, 2026 (timely).
• Exercise: 12,500 shares at $4.95 — total cost $61,875.
• Sales: 5,099 shares at a weighted avg $20.19 (proceeds $102,973; price range $19.67–$20.65 per F2) and 7,401 shares at a weighted avg $21.03 (proceeds $155,648; price range $20.67–$21.50 per F3).
• Combined sale proceeds: $258,621.
• Ownership after transaction: Not specified in the provided details of the filing.
• Footnotes of note:
  • F1: Sales were effected under a Rule 10b5-1 trading plan adopted June 24, 2026.
  • F2/F3: Reported sale prices are weighted averages; per-footnote ranges show individual trade prices.
  • F4: Vesting schedule for the option: 25% vested July 1, 2025, then 1/48th monthly thereafter, subject to continued service.
• No late filing flag indicated; filing appears within required Form 4 window.

Context

• The filing includes both an option exercise (derivative conversion) and same-day market sales. The presence of a Rule 10b5-1 plan (F1) indicates the sales were prearranged trading-plan transactions. One derivative line shows 12,500 shares "disposed" at $0 (reported as a derivative transaction) — the filing records this classification but gives no cash proceeds for that item. As always, purchases (exercises) can be seen as a more direct bullish signal than sales, but these sales were conducted under a pre-established 10b5-1 plan.